Clinical trial
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury and Major Adverse Kidney Events
NCT06602453 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury and Major Adverse Kidney Events
- Lead sponsor
- Genentech, Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- January 17, 2025
- Completion date
- March 3, 2026
- Enrollment
- 67 (actual)
- Sites
- 34
Conditions
As the registry lists them; a condition with its own page is linked.